BluGlass turns GaN laser demand into funded development work

Customer contracts expand while cash cover remains tight

BluGlass Limited (ASX:BLG) is turning more of its visible gallium nitride laser work into paid development, but the quarter also exposed the financing burden behind that strategy. The company reported a A$1.4 million Phase II contract with Uviquity, a new A$286,000 early-stage collaboration with a global photonics leader and A$8.66 million in quarter-end cash. On the Appendix 4C calculation, that cash represented 2.8 quarters of estimated funding at the quarter’s operating burn.

The Uviquity agreement extends a relationship that had already produced a A$1.4 million Uviquity contract into a broader second phase. The work now covers additional engineering, packaging, laser integration and purchases of BluGlass visible GaN lasers for Uviquity’s integrated photonics platform. BluGlass said its project-to-product model is intended to use paid development to meet customer-specific requirements and establish possible pathways to future product supply, although the update does not disclose contract margins or a production commitment.

New photonics study targets scientific and medical devices

The second commercial development is smaller but potentially relevant to the company’s attempt to build a broader customer pipeline. The approximately A$286,000 collaboration will run for three to five months and assess whether the two parties’ proprietary processes can be combined in a novel GaN-based device targeting scientific and medical applications. The feasibility program will examine device architectures, epitaxial structures, process integration and manufacturing techniques for visible-wavelength lasers.

The agreement is an early-stage technical assessment rather than a confirmed product order. The company described the partner as a global photonics leader, while recent coverage identified the collaboration as involving Coherent. BluGlass is contributing GaN epitaxy and semiconductor laser development capabilities, with the customer bringing photonics engineering, advanced manufacturing and commercialisation expertise. The next meaningful test is whether the feasibility work produces a defined development milestone or a supply opportunity.

Rockford facility boosts liquidity at a high cost

BluGlass replaced its A$2.27 million Radium facility with an A$8 million Rockford R&D financing facility during September. The company said the refinancing provided approximately A$5.4 million of additional liquidity, and the facility was fully drawn by 25 September. It carries interest of 16.5% a year, a 2.5% establishment fee and no undrawn funding remaining.

The financing had a visible effect on the quarter’s cash position. BluGlass used A$3.12 million in operating cash and A$2.42 million in investing activities, while financing activities contributed A$2.92 million after borrowings, repayments and related costs. The facility is secured against the FY26 and FY27 R&D Tax Incentive refunds, with limited security over other assets. The company subsequently received its A$6.1 million FY26 refund in October and applied A$2.75 million to the scheduled Rockford repayment; the remaining balance is to be repaid from the FY27 refund and no later than 1 March 2028.

Defence and US strategy remain part of the pipeline

During the quarter, BluGlass said it completed the third year of work under the US Microelectronics Commons program and continued multi-phase development with a Tier 1 US defence prime and a Fortune 500 data-storage company. It also presented its GaN laser strategy to US investors, with priorities including government engagement, technology partnerships and growth in defence, quantum, scientific, medical and advanced photonics applications.

The company appointed major shareholder and capital markets investor Yam Rubenstein as a non-executive director in August, while CEO Jim Haden became managing director in July. Those changes add capital-markets experience and align Haden’s title with responsibilities he was already performing, but the financial case still turns on execution: customer-funded programs need to progress without the operating burn outrunning receipts or the company needing another funding round.